Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results